Some 21 professional bodies, patient advocacy groups, healthcare campaigning organisations and private individuals took part in the process by sharing their views on a range of issues. These included:
The effectiveness of the code, including complaints, sanctions and procedures
The code's relevance to the current NHS
How the code might be updated/improved
Awareness and use of the code by the NHS, public and industry
The quality of promotional activity by the pharmaceutical industry
The ABPI Code of Practice covers pharmaceutical company promotion of prescription medicines to UK healthcare professionals in the UK and the provision of information to the public. It aims to safeguard the interests of patients and to ensure a responsible and ethical approach to such activities. Established in 1958 the Code is frequently updated. The last review in 2002 resulted in the current 2003 edition of the code. In addition, there are periodical full reviews - the current is the first since 1993.
The consultation submissions will be analysed by the review team over the next few weeks and the full review process is expected to reach completion by the end of 2005.
For further information, please contact: ABPI Press Office 020 7747 1410